Get started
Adaptive Biotechnologies CorporationAdaptive Biotechnologies CorporationAdaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ADPT chart


Full chart

ADPT upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪652.30 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.34 USD
Net income (FY)
‪−225.25 M‬ USD
Revenue (FY)
‪170.28 M‬ USD
Shares float
‪142.73 M‬
Beta (1Y)
1.72

Employees


Employees (FY)
709
Change (1Y)
−81 −10.25%
Revenue / Employee (1Y)
‪240.16 K‬ USD
Net income / Employee (1Y)
‪−317.70 K‬ USD

About Adaptive Biotechnologies Corporation


Sector
Health Technology
Industry
Biotechnology
CEO
Chad Robins
Website
adaptivebiotech.com
Headquarters
Seattle
Founded
2009
FIGI
BBG001J2PFF5
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

ADPT news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ADPT is 4.42 USD — it has decreased by −1.34% in the past 24 hours. Watch Adaptive Biotechnologies Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Adaptive Biotechnologies Corporation stocks are traded under the ticker ADPT.
ADPT stock has fallen by −26.33% compared to the previous week, the month change is a −4.12% fall, over the last year Adaptive Biotechnologies Corporation has showed a 0.45% increase.
We've gathered analysts' opinions on Adaptive Biotechnologies Corporation future price: according to them, ADPT price has a max estimate of 10.00 USD and a min estimate of 5.50 USD. Watch ADPT chart and read a more detailed Adaptive Biotechnologies Corporation stock forecast: see what analysts think of Adaptive Biotechnologies Corporation and suggest that you do with its stocks.
ADPT reached its all-time high on Jan 19, 2021 with the price of 71.25 USD, and its all-time low was 2.28 USD and was reached on Apr 19, 2024. View more price dynamics on ADPT chart.
See other stocks reaching their highest and lowest prices.
ADPT stock is 5.43% volatile and has beta coefficient of 1.72. Track Adaptive Biotechnologies Corporation stock price on the chart and check out the list of the most volatile stocks — is Adaptive Biotechnologies Corporation there?
Today Adaptive Biotechnologies Corporation has the market capitalization of ‪661.15 M‬, it has increased by 3.13% over the last week.
Yes, you can track Adaptive Biotechnologies Corporation financials in yearly and quarterly reports right on TradingView.
Adaptive Biotechnologies Corporation is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
ADPT earnings for the last quarter are −0.22 USD per share, whereas the estimation was −0.29 USD resulting in a 23.49% surprise. The estimated earnings for the next quarter are −0.26 USD per share. See more details about Adaptive Biotechnologies Corporation earnings.
Adaptive Biotechnologies Corporation revenue for the last quarter amounts to ‪46.44 M‬ USD, despite the estimated figure of ‪40.24 M‬ USD. In the next quarter, revenue is expected to reach ‪46.15 M‬ USD.
ADPT net income for the last quarter is ‪−32.07 M‬ USD, while the quarter before that showed ‪−46.22 M‬ USD of net income which accounts for 30.62% change. Track more Adaptive Biotechnologies Corporation financial stats to get the full picture.
No, ADPT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 709.00 employees. See our rating of the largest employees — is Adaptive Biotechnologies Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Adaptive Biotechnologies Corporation EBITDA is ‪−146.07 M‬ USD, and current EBITDA margin is −105.34%. See more stats in Adaptive Biotechnologies Corporation financial statements.
Like other stocks, ADPT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Adaptive Biotechnologies Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Adaptive Biotechnologies Corporation technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Adaptive Biotechnologies Corporation stock shows the sell signal. See more of Adaptive Biotechnologies Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.